- Long-term outcomes of patients with advanced hepatocellular carcinoma who achieved complete remission after sorafenib therapy
-
Park JG
- KMID: 2351029
- Clin Mol Hepatol.
- 2015 Sep;21(3):287-294.
- doi: 10.3350/cmh.2015.21.3.287
BACKGROUND/AIMS: Sorafenib is currently the sole molecular targeted agent that improves overall survival in advanced hepatocellular carcinoma (HCC). Despite the efficacy of sorafenib, the response rate varies in patients with... -
- CITED
-
- Close
- SHARE
-
- Close
